Sun pharma share price

While the NSE benchmark Nifty is close to its all-time high levels, half of the index constituents including Coal India, Tata Steel, Sun Pharma and ONGC are trading at valuations that are at steep discount to their 10-year averages. Some of these stocks have price targets that suggest potential upside ahead. In the case of ONGC, the oil refiner trades at 3.6 times its trailing 12-month earnings per share (EPS) compared with a 10-year average PE of 8.3 times, suggesting a discount of 56 per cent. The average target price of Rs 187 for ONGC, as suggested by Trendlyne, suggest a 20 per cent potential upside. Tata Steel at 9.3 times its trailing 12-month EPS stood at a 52 per cent per cent discount to a 10-year average of 19.4 times. The average target price of Rs 127 on this stock suggests 16 per cent potential upside. Coal India, which recently concluded its offer for sale (OFS), traded at a 33 per cent discount to historical PE average. Its PE stood at 7.3 times at the end of May against an average of 10.9 times for the 10-year period. Coal India shares can see 11 per cent upside potential, the average target price of Rs 255 on the stock suggests. Apollo Hospitals and Dr Reddy's Labs trade at discounts of 29 per cent and 28 per cent, respectively. Dr Reddy's Labs has an average price target of Rs 4,968, which suggests 8 per cent potential upside ahead. Target for Apollo Hospitals at Rs 5,238 also suggests a similar potential return ahead. None of banking, financial and insu...

Sector Healthcare Compare with Sector peers Industry Pharmaceuticals & Drugs Compare with Industry peers Website http://www.sunpharma.com Market Cap 237,090.29 Cr. Enterprise Value(EV) 237,517.88 Cr. 2023-03 Financial Indicators • Consolidated • Standalone Earnings per share (EPS) 35.32 Trailing Twelve Months Ending 2023-03 Price-Earning Ratio (PE) 27.98 Trailing Twelve Months Ending 2023-03 Industry PE 34.47 Trailing Twelve Months Ending 2023-03 Book Value / Share 233.38 Trailing Twelve Months Ending 2023-03 Price to Book Value 4.23 Calculated using Price: 988.15 Dividend Yield 1.16 Period Ending 2022-03 No. of Shares Subscribed 239.93 Cr. 2,399,334,970 Shares FaceValue 1 About Sun Pharmaceutical Industries Ltd. The company is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in many countries across the world, at affordable prices. 9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 Return on Equity (%) 23.15 24.89 19.32 22.51 6.85 8.05 9.66 4.98 7.21 Return on Capital Employed (%) 25.46 25.06 18.64 21.48 8.40 8.68 10.07 5.66 9.25 Return on Assets (%) 16.21 14.60 11.39 14.08 4.24 5.17 6.58 3.54 5.20 Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-...

Sun Pharmaceutical Industries’ share price fell 3.5 per cent intraday on Monday, despite a 43 per cent on-year growth in consolidated net profit at Rs 2,061 crore in FY23. The company reported a profit of Rs 1,444 crore in the corresponding quarter of previous year. The stock has risen 18.7 per cent in one year, and 8.3 per cent so far this year. The stock price has added 11 per cent in the last one month. At least three research and brokerage firms have recommended to buy the stock, and see up to 20 per cent upside potential. The Mumbai-based company had posted a net profit of Rs 1,444 crore in April-June period of 2021-22. Total revenue from operations rose to Rs 10,762 crore in the period under review from Rs 9,719 crore earlier, Sun Pharmaceutical Industries said in a regulatory filing. JM Financial Services BUY | Target price: Rs 1,130 | Upside: 20% Analysts say that Sun Pharmaceutical beats street expectations as support from domestic or specialty segments improve earnings trajectory making earnings upgrade imminent. “We maintain BUY, our top pick, at 25x 1Y forward earnings to derive a Jun’23 price target of Rs 1,130 apiece. It also added that the US and EM businesses continued momentum despite a high Covid base. Domestic business grew 2 per cent on-year led by healthy growth in Top 16-25 brands. Where is share market headed after Nifty closes above 18720, Bank Nifty above 44270; check support, resistance BUY | Target price: 1,100 | Upside: 17% Analysts have raised ...

Sun Pharmaceuticals share price fell 2% to hit an intraday low of Rs 856.7 on NSE on Tuesday after the drug maker reported a surprise net loss of Rs 2,227.38 crore for the quarter ended March 2022. Company’s revenue for the quarter rose 11% from a year ago to Rs 9,386.08 crore. The firm also reappointed Dilip Shanghvi as a managing director for a further term of five years and Pawan Goenka was appointed lead independent director. So far this year, Sun Pharma stock has outperformed benchmarks. Sun Pharma share price has risen 3.49% year-to-date as opposed to 6% fall in NSE Nifty 50. Analysts remain bullish on the stock and see up to 22% potential rally going forward on the back of scale-up of the Specialty portfolio, niche launches in the US generics segment. Stock talk: Should you buy, hold or sell Sun Pharma shares? Motilal Oswal: Buy Target price: Rs 1,040; Upside: 17% According to analysts at Motilal Oswal Financial Services, Sun pharma delivered a lower-than-expected 4QFY22 due to moderation in the RoW/EMs/API segment and higher OPEX. However, company’s Specialty portfolio continues to progress well, with its contribution to sales rising to 13% in FY22 from 7% in FY18. Analysts tweaked their FY23, FY24 EPS estimate by around 4% and 3% respectively factoring in a higher R&D spend on clinical trials, high OPEX-related to promotional activities and supply chain management; and weakness in API offtake to some extent. “We value SUNP at 25x 12-month forward earnings to arriv...